Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × Sorafenib × 90 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 7 Leukemia, Myeloid, Acute 3 Fibrolamellar hepatocellular carcinoma 2 Tongue Neoplasms 1 Thyroid cancer, Hurthle cell 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms 1 Myelodysplastic Syndromes 1 Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors 1 Melanoma 1 Hepatoblastoma 1 Desmoplastic Small Round Cell Tumor 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 27 Nivolumab 23 cabozantinib 22 Magnetic Resonance Spectroscopy 20 Specimen Handling 16 Ipilimumab 14 lenvatinib 10 belzutifan 7 Biopsy 7 Axitinib 7 Sunitinib 6 Everolimus 6 CTLA-4 Antigen 6 avelumab 5 atezolizumab 5 aldesleukin 5 Immunoglobulin G 5 Bevacizumab 5 pazopanib 4 fludarabine 4 Radiosurgery 4 Disulfides 4 Cyclophosphamide 4 palbociclib 3 cemiplimab 3 Nephrectomy 3 IFL protocol 3 zimberelimab 2 toripalimab 2 spartalizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02184416 2026-02-27

ADONIS

Pfizer

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡